Pharma inventory that gives generic formulations and API merchandise, together with anti-diabetics, immunosuppressants, and lots of extra in focus after receiving US FDA’s approval for Key Most cancers medicine.
Worth Motion
With a market capitalization of ₹38,251 Crores the shares of Biocon rallied to right now’s day excessive of ₹324.90 on the BSE on 5 march, 2025, up by 3.1% from its earlier day closing value of ₹314.80.
Purpose
Biocon Pharma Restricted (the totally owned subsidiary) of Biocon acquired ultimate approval for its following ANDAs from the U.S. Meals and Drug Administration (U.S. FDA):
- Lenalidomide Capsules – It’s a treatment used to deal with sorts of a number of myeloma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and anemia in myelodysplastic syndromes (MDS) in adults.
- Dasatinib Tablets- This treatment is used to deal with sure sorts of most cancers (persistent myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It really works by slowing or stopping the expansion of most cancers cells
- Biocon Pharma Restricted additionally acquired tentative approval of its ANDA for Rivaroxaban Tablets USP. Rivaroxaban is used within the remedy of deep vein thrombosis and pulmonary embolism to cut back the danger of stroke and systemic embolism in nonvalvular atrial fibrillation,.and so forth.
These approvals additional add to Biocon’s portfolio of vertically built-in, advanced drug merchandise
Additionally learn: Energy transmission inventory jumps 4% after receiving ₹500 Cr order from Energy Grid Corpo
Monetary Highlights
The corporate reported a income of ₹3,821 crores in Q3 FY25 which is 6.43% up from the earlier quarter of ₹3,590 crores. The corporate has maintained a wholesome common working revenue margin of 20%. Its internet revenue elevated by over 200% (₹81 crores) within the newest quarter of Q3 FY25 as in comparison with the earlier quarter of solely ₹27 crores.
The corporate’s consolidated internet revenue dropped to ₹25.1 crores in Q3 FY25, in comparison with ₹660 crores in Q3 FY24, whereas income stood at ₹3,821 crore within the newest quarter, down from ₹3,954 crore on a YoY foundation.
Future Plans
The corporate plans to record its key Biosimilar enterprise by March, 2026 and launch its 5 new biosimilars within the USA market within the new fiscal 12 months by April, 2025 and the administration are optimistic about scoring double-digit market share. It goals to be one of many high three biosimilar corporations globally by way of strategic launches and partnerships.
About Firm
Biocon Restricted, along with its subsidiaries, engages within the manufacture and sale of biotechnology merchandise and analysis companies in India, Brazil, Singapore, and internationally. It operates by way of 4 segments: Generics, Novel Biologics, Biosimilars, and Analysis Companies.
The corporate provides generic formulations and API merchandise, together with anti-diabetics, immunosuppressants, a number of sclerosis, anti-cancer/oncology, and different merchandise; novel biologics merchandise, resembling head and neck most cancers molecule; novel pipeline merchandise comprising psoriasis molecules; and biosimilars merchandise consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab.
It additionally gives built-in discovery, improvement, and manufacturing companies to pharmaceutical, biotechnology, animal healthcare, client items, and agrochemical corporations. Biocon Restricted was integrated in 1978 and is headquartered in Bengaluru, India.
Written by Satyajeet Mukherjee
Disclaimer
The views and funding suggestions expressed by funding specialists/broking homes/score companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a danger of monetary losses. Traders should subsequently train due warning whereas investing or buying and selling in shares. Dailyraven Applied sciences or the creator should not chargeable for any losses brought on on account of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
